Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary

Urology. 2021 Sep:155:165-171. doi: 10.1016/j.urology.2020.12.021. Epub 2020 Dec 26.

Abstract

Androgen deprivation therapy remains the backbone therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). In recent years, several treatments, including docetaxel, abiraterone + prednisone, enzalutamide, and apalutamide, have each been shown to demonstrate survival benefit when used upfront along with androgen deprivation therapy. However, treatment selection for an individual patient remains a challenge. There is no high level clinical evidence for treatment selection among these choices based on biological drivers of clinical disease. In August 2020, the Prostate Cancer Foundation convened a working group to meet and discuss biomarkers for hormone-sensitive prostate cancer, the proceedings of which are summarized here. This meeting covered the state of clinical and biological evidence for systemic therapies in the mHSPC space, with emphasis on charting a course for the generation, interrogation, and clinical implementation of biomarkers for treatment selection.

Publication types

  • Congress

MeSH terms

  • Biomarkers, Tumor / blood
  • Biomarkers, Tumor / genetics*
  • DNA, Neoplasm / blood
  • Hormone Antagonists / therapeutic use
  • Hormones / therapeutic use*
  • Humans
  • Male
  • Multienzyme Complexes / genetics
  • Nuclear Proteins / genetics
  • Oncogene Proteins, Fusion / genetics
  • Orchiectomy
  • PTEN Phosphohydrolase / genetics
  • Progesterone Reductase / genetics
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / therapy*
  • Prostatic Neoplasms, Castration-Resistant
  • Randomized Controlled Trials as Topic
  • Receptors, Androgen / genetics
  • Repressor Proteins / genetics
  • Research Design
  • Retinoblastoma Binding Proteins / genetics
  • Steroid Isomerases / genetics
  • Terminology as Topic
  • Tumor Suppressor Protein p53 / genetics
  • Ubiquitin-Protein Ligases / genetics

Substances

  • 3 beta-hydroxysteroid oxidoreductase-delta(5) 3-ketosteroid isomerase
  • Biomarkers, Tumor
  • DNA, Neoplasm
  • Hormone Antagonists
  • Hormones
  • Multienzyme Complexes
  • Nuclear Proteins
  • Oncogene Proteins, Fusion
  • RB1 protein, human
  • Receptors, Androgen
  • Repressor Proteins
  • Retinoblastoma Binding Proteins
  • SPOP protein, human
  • TMPRSS2-ERG fusion protein, human
  • TP53 protein, human
  • Tumor Suppressor Protein p53
  • Progesterone Reductase
  • Ubiquitin-Protein Ligases
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Steroid Isomerases